The Experts below are selected from a list of 4164 Experts worldwide ranked by ideXlab platform
Rashid M Rashid - One of the best experts on this subject based on the ideXlab platform.
-
308 nm excimer laser in Psoriasis Vulgaris scalp Psoriasis and palmoplantar Psoriasis
Journal of The European Academy of Dermatology and Venereology, 2009Co-Authors: S Gattu, Rashid M RashidAbstract:Background The 308-nm excimer laser is a recent development in the treatment of Psoriasis Vulgaris, palmoplantar Psoriasis, and Psoriasis of the scalp. The XeCl excimer emits a 308-nm wavelength beam of light that is monochromatic and coherent. These properties allow selectivity when used as phototherapy against a psoriatic lesion while sparing healthy surrounding tissue. Objective In this manuscript, we review recent updates on the efficacy of excimer and its most recent trials in Psoriasis. Methods A review of the medical literature in Pubmed database was performed using the terms 'Psoriasis' and '308 nm excimer laser'. All trials to date that studied the 308-nm excimer including those that compared the excimer with other modalities were included. Results Eighteen trials show positive results surrounding the efficacy of the excimer. Selectivity of the 308-nm excimer, when compared with non-selective narrowband UVB (NB-UVB) phototherapy allows one to adjust the fluency to the lesion. The excimer may also stand superior to NB-UVB in its efficacy of mechanism. Conclusion Excimer is a useful and effective treatment for Psoriasis that may be used as a compliment to topical medications as well as NB-UVB. However, large randomized trials with long-term follow-up are needed to further support this.
S Gattu - One of the best experts on this subject based on the ideXlab platform.
-
308 nm excimer laser in Psoriasis Vulgaris scalp Psoriasis and palmoplantar Psoriasis
Journal of The European Academy of Dermatology and Venereology, 2009Co-Authors: S Gattu, Rashid M RashidAbstract:Background The 308-nm excimer laser is a recent development in the treatment of Psoriasis Vulgaris, palmoplantar Psoriasis, and Psoriasis of the scalp. The XeCl excimer emits a 308-nm wavelength beam of light that is monochromatic and coherent. These properties allow selectivity when used as phototherapy against a psoriatic lesion while sparing healthy surrounding tissue. Objective In this manuscript, we review recent updates on the efficacy of excimer and its most recent trials in Psoriasis. Methods A review of the medical literature in Pubmed database was performed using the terms 'Psoriasis' and '308 nm excimer laser'. All trials to date that studied the 308-nm excimer including those that compared the excimer with other modalities were included. Results Eighteen trials show positive results surrounding the efficacy of the excimer. Selectivity of the 308-nm excimer, when compared with non-selective narrowband UVB (NB-UVB) phototherapy allows one to adjust the fluency to the lesion. The excimer may also stand superior to NB-UVB in its efficacy of mechanism. Conclusion Excimer is a useful and effective treatment for Psoriasis that may be used as a compliment to topical medications as well as NB-UVB. However, large randomized trials with long-term follow-up are needed to further support this.
Wu-chang Yang - One of the best experts on this subject based on the ideXlab platform.
-
lipoprotein glomerulopathy associated with Psoriasis Vulgaris report of 2 cases with apolipoprotein e3 3
American Journal of Kidney Diseases, 2003Co-Authors: Chao-fu Chang, Ming-shi Shiao, Chih-ching Lin, Jinn-yang Chen, An-hang Yang, Jau-tsuen Kao, Wu-chang YangAbstract:Lipoprotein glomerulopathy (LPG) is a rare disease, characterized by a special histology, including dilated glomerular capillaries filled with pale-stained and meshlike lipoprotein thrombi. It always presents with proteinuria or nephrotic syndrome. Although hyperlipidemia is not always seen, most patients have type III hyperlipoproteinemia with apolipoprotein (apo) E2/3 phenotyping. Although the clinical feature of LPG is rarely described, LPG associated with other glomerulopathy, including IgA nephropathy, membranous nephropathy, and lupus nephritis, has been documented. Until now, there have been no reports of Psoriasis Vulgaris associated with LPG. The authors present 2 cases of LPG with apo E3/3 genotyping associated with Psoriasis Vulgaris. The first patient was a 65-year-old woman who presented with nephrotic syndrome with daily urinary protein loss of 9.05 g and itchy erythematous scaly plaques on her trunk and lower limbs for 1 year. The renal biopsy results showed LPG, and the skin biopsy results showed Psoriasis. The second patient was a 50-year-old man with history of Psoriasis over his trunk and 4 limbs for 30 years. He also presented with nephrotic syndrome with daily urinary protein loss of 7.55 g. The renal biopsy results also showed LPG. The genotype of apo E showed E3/3, and lipoprotein electrophoresis showed a type III hyperlipoproteinemia-like pattern in both cases. The authors suggest that presence of apo E3/3 genotype cannot rule out the diagnosis of type III hyperlipoproteinemia and LPG. Besides, LPG should be included in the differential diagnosis of psoriatic patients with nephrotic syndrome, especially in Asian patients who show poor response to traditional therapy. Renal biopsy should be performed to make the definitive diagnosis.
-
Lipoprotein glomerulopathy associated with Psoriasis Vulgaris: report of 2 cases with apolipoprotein E3/3.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003Co-Authors: Chao-fu Chang, Ming-shi Shiao, Chih-ching Lin, Jinn-yang Chen, An-hang Yang, Jau-tsuen Kao, Wu-chang YangAbstract:Lipoprotein glomerulopathy (LPG) is a rare disease, characterized by a special histology, including dilated glomerular capillaries filled with pale-stained and meshlike lipoprotein thrombi. It always presents with proteinuria or nephrotic syndrome. Although hyperlipidemia is not always seen, most patients have type III hyperlipoproteinemia with apolipoprotein (apo) E2/3 phenotyping. Although the clinical feature of LPG is rarely described, LPG associated with other glomerulopathy, including IgA nephropathy, membranous nephropathy, and lupus nephritis, has been documented. Until now, there have been no reports of Psoriasis Vulgaris associated with LPG. The authors present 2 cases of LPG with apo E3/3 genotyping associated with Psoriasis Vulgaris. The first patient was a 65-year-old woman who presented with nephrotic syndrome with daily urinary protein loss of 9.05 g and itchy erythematous scaly plaques on her trunk and lower limbs for 1 year. The renal biopsy results showed LPG, and the skin biopsy results showed Psoriasis. The second patient was a 50-year-old man with history of Psoriasis over his trunk and 4 limbs for 30 years. He also presented with nephrotic syndrome with daily urinary protein loss of 7.55 g. The renal biopsy results also showed LPG. The genotype of apo E showed E3/3, and lipoprotein electrophoresis showed a type III hyperlipoproteinemia-like pattern in both cases. The authors suggest that presence of apo E3/3 genotype cannot rule out the diagnosis of type III hyperlipoproteinemia and LPG. Besides, LPG should be included in the differential diagnosis of psoriatic patients with nephrotic syndrome, especially in Asian patients who show poor response to traditional therapy. Renal biopsy should be performed to make the definitive diagnosis.
Lotte Vestergaard Tingleff - One of the best experts on this subject based on the ideXlab platform.
-
calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of Psoriasis Vulgaris a randomised parallel group double blind exploratory study
European Journal of Dermatology, 2010Co-Authors: Colin Fleming, Cecilia Ganslandt, Lyn Guenther, Anders Johannesson, Colin Buckley, Jan C Simon, Helen Stegmann, Lotte Vestergaard TingleffAbstract:A two-compound ointment containing calcipotriol plus betamethasone dipropionate is an effective treatment for Psoriasis Vulgaris. The same active ingredients have now been combined in a gel formulation. Our objective was to compare the efficacy and safety of once daily treatment of the two-compound gel with the single components in the same gel vehicle and the gel vehicle alone, in patients with Psoriasis Vulgaris on the trunk and/or limbs. 364 patients received once daily treatment for up to 8 weeks with either the two-compound gel, the single components in the gel vehicle or the gel vehicle alone. The percentage of patients whose disease was clear or very mild and who had at least a two-step improvement in the Investigator's Global Assessment of disease severity at week 8, was significantly higher with calcipotriol plus betamethasone dipropionate (27.2%) than with betamethasone dipropionate (16.9%, p = 0.027), calcipotriol (11.4%, p = 0.006) or gel vehicle (0.0%, p < 0.001). This exploratory study showed that the two-compound gel was safe and more efficacious than its individual ingredients in the treatment of Psoriasis Vulgaris.
Jan C Simon - One of the best experts on this subject based on the ideXlab platform.
-
calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of Psoriasis Vulgaris a randomised parallel group double blind exploratory study
European Journal of Dermatology, 2010Co-Authors: Colin Fleming, Cecilia Ganslandt, Lyn Guenther, Anders Johannesson, Colin Buckley, Jan C Simon, Helen Stegmann, Lotte Vestergaard TingleffAbstract:A two-compound ointment containing calcipotriol plus betamethasone dipropionate is an effective treatment for Psoriasis Vulgaris. The same active ingredients have now been combined in a gel formulation. Our objective was to compare the efficacy and safety of once daily treatment of the two-compound gel with the single components in the same gel vehicle and the gel vehicle alone, in patients with Psoriasis Vulgaris on the trunk and/or limbs. 364 patients received once daily treatment for up to 8 weeks with either the two-compound gel, the single components in the gel vehicle or the gel vehicle alone. The percentage of patients whose disease was clear or very mild and who had at least a two-step improvement in the Investigator's Global Assessment of disease severity at week 8, was significantly higher with calcipotriol plus betamethasone dipropionate (27.2%) than with betamethasone dipropionate (16.9%, p = 0.027), calcipotriol (11.4%, p = 0.006) or gel vehicle (0.0%, p < 0.001). This exploratory study showed that the two-compound gel was safe and more efficacious than its individual ingredients in the treatment of Psoriasis Vulgaris.
